.”
“A new soluble polythiophene copolymer with thiophene-vinylene conjugated side chain poly[3-(5'-octylthienylenevinyl) thiophene]-thiophene (POTVTh-Th) was successfully synthesized and characterized using NMR, UV-visible spectroscopy, etc. To study the photovoltaic property of the copolymer, photovoltaic device of ITO/PEDOT:PSS/POTVTh-Th:[6,6]-phenyl C61-butyric acid methyl ester (PC61BM) (weight ratio being 1 : 1)/LiF/Al
was fabricated, in which POTVTh-Th acted as the electron donor in the active layer. Under 100 mW/cm(2) AM 1.5G simulated solar emission, the open-circuit voltage and Crenolanib price the short-circuit current density of the device were 0.58 V and 2.50 mA/cm(2), respectively. The power conversion efficiency and the fill factor of the photovoltaic device were evaluated to be 0.42% and 0.30. (C) 2011 Wiley Periodicals, Inc. J Appl Polym Sci, 2012″
“Background: Neisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries. A Haemophilus influenzae type b-meningococcal serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) was evaluated.
Methods: A total of 1104 infants (randomized
3: 1: 1) were vaccinated at 2, 4, and 6 months with HibMenCY-TT, MenC-CRM(197) + Hib-TT, or Hib-TT. At 12 to 15 months, HibMenCY-TT and MenC-CRM-primed children received HibMenCY-TT; Hib-TT-primed received N. meningitidis serogroup B Hib-outer membrane protein complex. Selleckchem GSK2118436 Antibody concentrations and rabbit/human complement serum bactericidal antibody
titers (rSBA/hSBA) were SNS-032 determined. Safety was monitored after each dose (diary cards for first 31 days) until 6 months postdose 4.
Results: Postdose 3, rates of antipolyribosylribitol phosphate >= 1 mu g/mL and rSBA-MenC >= 1:128 in HibMenCY-TT recipients were noninferior to licensed controls. Percentages reaching 0.15 mu g/mL (1.0 mu g/mL postdose 3) and antipolyribosylribitol phosphate GMC were significantly higher after HibMenCY-TT than Hib-TT postdose 2 and postdose 3. The GMC remained significantly higher before and after dose 4. Proportions of HibMenCY-TT recipients with rSBA >= 1:8 were 95.6% (MenC), 98.6% (MenY) postdose-2, >= 99% for MenC/Y postdose 3 and 4; hSBA >= 1:4 were 95.5% (MenC), 89.8% (MenY) postdose 2, >97% for MenC/Y postdose 3 and 4. HibMenCY-TT had a similar safety profile to control vaccines.
Conclusions: HibMenCY-TT induced noninferior Hib and MenC responses compared with monovalent Hib and MenC conjugates with a comparable safety profile. Bactericidal antibodies against MenC/Y were induced after 2 doses of HibMenCY-TT.”
“Southeast Asia will likely be the epicenter of the next influenza pandemic. To determine whether health system resources in Thailand are sufficient to contain an emerging pandemic, we mapped health system resources in 76 provinces. We used 3 prepandemic scenarios of clustered cases and determined resource needs, availability, an gaps.